Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...